Literature DB >> 20422063

Direct health care costs associated with asthma in British Columbia.

Mohsen Sadatsafavi1, Larry Lynd, Carlo Marra, Bruce Carleton, Wan C Tan, Sean Sullivan, J Mark Fitzgerald.   

Abstract

BACKGROUND: A better understanding of health care costs associated with asthma would enable the estimation of the economic burden of this increasingly common disease.
OBJECTIVE: To determine the direct medical costs of asthma-related health care in British Columbia (BC).
METHODS: Administrative health care data from the BC Linked Health Database and PharmaNet database from 1996 to 2000 were analyzed for BC residents five to 55 years of age, including the billing information for physician visits, drug dispensations and hospital discharge records. A unit cost was assigned to physician/emergency department visits, and government reimbursement fees for prescribed medications were applied. The case mix method was used to calculate hospitalization costs. All costs were reported in inflation-adjusted 2006 Canadian dollars.
RESULTS: Asthma resulted in $41,858,610 in annual health care-related costs during the study period ($331 per patient-year). The major cost component was medications, which accounted for 63.9% of total costs, followed by physician visits (18.3%) and hospitalization (17.8%). When broader definitions of asthma-related hospitalizations and physician visits were used, total costs increased to $56,114,574 annually ($444 per patient-year). There was a statistically significant decrease in the annual per patient cost of hospitalizations (P<0.01) over the study period. Asthma was poorly controlled in 63.5% of patients, with this group being responsible for 94% of asthma-related resource use.
CONCLUSION: The economic burden of asthma is significant in BC, with the majority of the cost attributed to poor asthma control. Policy makers should investigate the reason for lack of proper asthma control and adjust their policies accordingly to improve asthma management.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20422063      PMCID: PMC2866215          DOI: 10.1155/2010/361071

Source DB:  PubMed          Journal:  Can Respir J        ISSN: 1198-2241            Impact factor:   2.409


  26 in total

1.  Patterns of inhaled asthma medication use: a 3-year longitudinal analysis of prescription claims data from British Columbia, Canada.

Authors:  Larry D Lynd; Daphne P Guh; Peter D Paré; Aslam H Anis
Journal:  Chest       Date:  2002-12       Impact factor: 9.410

Review 2.  The global burden of asthma: executive summary of the GINA Dissemination Committee report.

Authors:  Matthew Masoli; Denise Fabian; Shaun Holt; Richard Beasley
Journal:  Allergy       Date:  2004-05       Impact factor: 13.146

3.  An economic evaluation of asthma in the United States.

Authors:  K B Weiss; P J Gergen; T A Hodgson
Journal:  N Engl J Med       Date:  1992-03-26       Impact factor: 91.245

Review 4.  Compensation for occupational asthma in Quebec.

Authors:  J L Malo
Journal:  Chest       Date:  1990-11       Impact factor: 9.410

5.  A national estimate of the economic costs of asthma.

Authors:  D H Smith; D C Malone; K A Lawson; L J Okamoto; C Battista; W B Saunders
Journal:  Am J Respir Crit Care Med       Date:  1997-09       Impact factor: 21.405

Review 6.  Inhaled corticosteroids: impact on asthma morbidity and mortality.

Authors:  S Suissa; P Ernst
Journal:  J Allergy Clin Immunol       Date:  2001-06       Impact factor: 10.793

7.  Control of asthma in Canada: failure to achieve guideline targets.

Authors:  K R Chapman; P Ernst; A Grenville; P Dewland; S Zimmerman
Journal:  Can Respir J       Date:  2001 Mar-Apr       Impact factor: 2.409

8.  A comprehensive study of the direct and indirect costs of adult asthma.

Authors:  Miriam G Cisternas; Paul D Blanc; Irene H Yen; Patricia P Katz; Gillian Earnest; Mark D Eisner; Stephen Shiboski; Edward H Yelin
Journal:  J Allergy Clin Immunol       Date:  2003-06       Impact factor: 10.793

9.  Asthma severity and medical resource utilisation.

Authors:  L Antonicelli; C Bucca; M Neri; F De Benedetto; P Sabbatani; F Bonifazi; H G Eichler; Q Zhang; D D Yin
Journal:  Eur Respir J       Date:  2004-05       Impact factor: 16.671

10.  Direct and indirect costs of asthma in Canada, 1990.

Authors:  M D Krahn; C Berka; P Langlois; A S Detsky
Journal:  CMAJ       Date:  1996-03-15       Impact factor: 8.262

View more
  43 in total

Review 1.  Obesity and severe asthma.

Authors:  Hiroki Tashiro; Stephanie A Shore
Journal:  Allergol Int       Date:  2018-12-01       Impact factor: 5.836

2.  A paradigm shift in the treatment of mild asthma?

Authors:  Wei Tang; Lin Sun; J Mark FizGerald
Journal:  J Thorac Dis       Date:  2018-10       Impact factor: 2.895

3.  Organization, Clinical and Management Indicators on the First Year of Activity of an Outpatient Clinic Dedicated to the Diagnosis and Treatment of Severe Asthma in Italy.

Authors:  Silvia Tognella; Claudio Micheletto; Alessandro Roggeri; Guido Polese; Denise Artioli; Gianenrico Senna; Marco Caminati; Daniela Paola Roggeri
Journal:  J Asthma Allergy       Date:  2021-08-13

4.  Bronchoscopic Targeted Lung Denervation in Patients with Severe Asthma: Preliminary Findings.

Authors:  Jorine E Hartman; Karthi Srikanthan; Cielito Caneja; Nick H T Ten Hacken; Huib A M Kerstjens; Pallav L Shah; Dirk-Jan Slebos
Journal:  Respiration       Date:  2021-09-01       Impact factor: 3.966

5.  Autophagy-Related Genes Are Involved in the Progression and Prognosis of Asthma and Regulate the Immune Microenvironment.

Authors:  Fan Yang; Jingwei Kong; Yuhan Zong; Zhuqing Li; Mingsheng Lyu; Wanyang Li; Wenle Li; Haoyue Zhu; Shunqi Chen; Xiaoshan Zhao; Ji Wang
Journal:  Front Immunol       Date:  2022-05-10       Impact factor: 8.786

6.  Comparison of clinical characteristics and management of asthma by types of health care in South Korea.

Authors:  Eun Yeong Cho; Ki Jong Oh; Chin Kook Rhee; Kwang Ha Yoo; Bo Yeon Kim; Hye Won Bae; Byung-Jae Lee; Dong-Chull Choi; Hyun Lee; Hye Yun Park
Journal:  J Thorac Dis       Date:  2018-06       Impact factor: 2.895

7.  Combination fixed-dose beta agonist and steroid inhaler as required for adults or children with mild asthma.

Authors:  Iain Crossingham; Sally Turner; Sanjay Ramakrishnan; Anastasia Fries; Matthew Gowell; Farhat Yasmin; Rebekah Richardson; Philip Webb; Emily O'Boyle; Timothy Sc Hinks
Journal:  Cochrane Database Syst Rev       Date:  2021-05-04

8.  Current recommendations for the treatment of mild asthma.

Authors:  Neal Shahidi; J Mark Fitzgerald
Journal:  J Asthma Allergy       Date:  2010-12-08

9.  Effect of omalizumab as add-on therapy to Quality of Life Questionnaire for Korean Asthmatics (KAQLQ) in Korean patients with severe persistent allergic asthma.

Authors:  Jae-Woo Jung; Hae-Sim Park; Choon-Sik Park; Sang-Heon Cho; Inseon S Choi; Hee-Bom Moon; Soon Seog Kwon; Ho Joo Yoon; Jung Won Park; Jong-Myung Lee; Dong-Chull Choi; Byoung Whui Choi
Journal:  Korean J Intern Med       Date:  2021-06-01       Impact factor: 2.884

10.  Combination fixed-dose β agonist and steroid inhaler as required for adults or children with mild asthma: a Cochrane systematic review.

Authors:  Iain Crossingham; Sally Turner; Sanjay Ramakrishnan; Anastasia Fries; Matthew Gowell; Farhat Yasmin; Rebekah Richardson; Philip Webb; Emily O'Boyle; Timothy Stopford Christopher Hinks
Journal:  BMJ Evid Based Med       Date:  2021-07-19
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.